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Abstract.19
Background: Diagnosis of Alzheimer’s disease (AD) confirmed by biomarkers allows the patient to make important life
decisions. However, doubt about the fleetness of symptoms progression and future cognitive decline remains. Neuropsycho-
logical measures were extensively studied in prediction of time to conversion to dementia for mild cognitive impairment
(MCI) patients in the absence of biomarker information. Similar neuropsychological measures might also be useful to predict






Objective: To study the contribution of neuropsychological measures to predict time to conversion to dementia in patients
with MCI due to AD.
25
26
Methods: Patients with MCI due to AD were enrolled from a clinical cohort and the effect of neuropsychological performance
on time to conversion to dementia was analyzed.
27
28
Results: At baseline, converters scored lower than non-converters at measures of verbal initiative, non-verbal reasoning,
and episodic memory. The test of non-verbal reasoning was the only statistically significant predictor in a multivariate Cox
regression model. A decrease of one standard deviation was associated with 29% of increase in the risk of conversion to
dementia. Approximately 50% of patients with more than one standard deviation below the mean in the z score of that test
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Conclusion: In MCI due to AD, lower performance in a test of non-verbal reasoning was associated with time to conversion to
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Nowadays, the development and clinical appli-35
cation of biomarkers has dramatically changed the36
framework of Alzheimer’s disease (AD) diagno-37
sis. It is now possible to diagnose AD at an early38
pre-dementia stage, that is, before the patient has39
symptoms severe enough to be considered demented40
[1, 2]. Different diagnostic criteria with slight differ-41
ences were advanced, namely prodromal AD [3–5]42
and mild cognitive impairment (MCI) due to AD43
[6], that rely on biomarkers reflecting pathological44
alterations in the brain typical of AD, namely: 1)45
decline in episodic memory, confirmed by neuropsy-46
chological testing, 2) atrophy of the hippocampus and47
other medial temporal lobe structures shown by mag-48
netic resonance imaging, 3) detection of abnormal49
cerebrospinal fluid (CSF) biomarkers, namely low50
amyloid amyloid- (A)42 concentrations, increased51
phosphorylated tau or total tau concentrations, 4)52
abnormal brain deposits of A and tau, as well53
as reduced glucose metabolism in temporoparietal54
regions, by positron emission tomography (PET55
scan). The use of biomarkers for diagnosis of MCI56
due to AD quickly spread to AD reference centers57
[7] and more sluggishly to routine clinical practice.58
Uncertainties remain about the possible benefits59
and disadvantages of obtaining and communicating60
a specific diagnosis of prodromal AD, or MCI due61
to AD, to an individual patient. On the one hand,62
it should be relevant for the patient to make life63
decisions and prepare the near future, engage in a64
cognitive rehabilitation program, start appropriate65
pharmacological therapy, and eventually participate66
in a clinical trial. On the other hand, it might upset67
patients and caregivers, leading to emotional dis-68
tress and concerns about progression of symptoms69
and the fleetness of future cognitive decline [8]. One70
important present limitation of obtaining and com-71
municating a specific diagnosis of MCI due to AD is72
that the actual pace of disease progression, attainment73
of important clinical milestones, and in particular74
conversion to dementia, are presently impossible to75
predict in an individual basis. This point could not76
be made more clearly than by the patient’s sentence 77
when receiving the diagnosis of MCI due to AD: Yes, 78
I hope for the best. It will definitely evolve. I don’t 79
think it will stay like that, but is that within 5 years? 80
[8]. 81
Importantly, prediction of time to conversion to 82
dementia has already been extensively studied in 83
MCI without the information of biomarkers, namely 84
using neuropsychological assessments. These studies 85
showed that memory tests, as well as executive func- 86
tion and verbal fluency tests, are able to predict with 87
accuracy the time to conversion to dementia [9–25]. 88
We hypothesize that similar neuropsychological mea- 89
sures may also be useful to predict the progression 90
to dementia in MCI due to AD. It should be very 91
important to provide the individual patient diagnosed 92
with MCI due to AD with reliable information on the 93
prediction of stability or conversion to dementia at a 94
clinically relevant time window. 95
METHODS 96
Participants 97
A cohort of 232 patients who attended neurologic 98
consultation in a private memory clinic in Lisbon 99
(Memoclı́nica) and Coimbra University Hospital, in 100
Coimbra, from 2006 to 2017, performed a com- 101
prehensive neuropsychological evaluation and were 102
tested for biomarkers of brain amyloidosis and neu- 103
ronal injury. From these, 127 had the diagnosis of 104
MCI due to AD and were included in the present 105
study. Patients had to have associated follow-up infor- 106
mation and to be followed for at least one year, thus 107
only 110 patients were analyzed for the present study 108
(Fig. 1). 109
Ethical guidelines 110
The study was conducted in accordance with the 111
Declaration of Helsinki, and the local ethics commit- 112
tee approved the study. All patients provided their 113
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Fig. 1. Flow-chart of patient selection for the study.
Diagnostic criteria114
The diagnostic criteria of MCI due to AD, as115
proposed by the National Institute on Aging -116
Alzheimer’s Association workgroups [6], offer the117
most accurate prognosis in clinical settings [26].118
Specifically, the criteria of MCI due to AD–High119
Likelihood [6] were considered in the present study120
since they provide the highest degree of certainty that121
the patient will progress to AD dementia:122
1. Clinical and cognitive criteria123
a. Cognitive concern reflecting a change in124
cognition reported by patient, informant,125
or clinician126
b. Objective evidence of impairment in one127
or more cognitive domains, typically128
including memory129
c. Preservation of independence in func-130
tional abilities131
d. Not demented132
2. Etiology of MCI consistent with AD pathophys-133
iological process134
a. Vascular, traumatic and medical causes of135
cognitive decline were ruled out136
b. Evidence of longitudinal decline in cogni-137
tion (when feasible)138
3. Biomarkers of A deposition139
a. Low CSF A42 and/or140
b. Positive amyloid PiB-PET imaging.141
4. Biomarkers of neuronal injury (at least one142
present)143
a. High CSF total tau or hyperphosphorylated tau, 144
and/or 145
b. Medial temporal atrophy by volumetric mea- 146
sures or visual rating, and/or 147
c. Temporoparietal hypometabolism by FDG-PET 148
imaging 149
Both sources of amyloid status (CSF and PiB- 150
PET) were considered interchangeable since a 151
high agreement between A42 concentrations in 152
the CSF and amyloid PiB-PET scan results in 153
MCI and AD patients was confirmed by previ- 154
ous studies [27]. All procedures were performed 155
according to the established protocols on participat- 156
ing centers [28–32]. The levels of A42, total tau 157
(t-tau), and hyperphosphorylated tau (p-tau) were 158
measured using commercially available enzyme- 159
linked immunosorbent assays (INNOTEST® A42, 160
INNOTEST hTAU Ag and INNOTEST PHOSPHO- 161
TAU(181P); Innogenetics, Ghent, Belgium). The 162
expected site assay variability present in multicen- 163
ter studies was acknowledged [33] and positivity 164
was determined using locally available cut-off values. 165
Amyloid PET scans used the Pittsburgh Compound 166
B (11C-PIB) and were performed in the same scan- 167
ner (Philips PET/CT Gemini GXL), preceded by a 168
low-dose brain computed tomography (CT) acquisi- 169
tion for attenuation correction (Institute of Nuclear 170
Science Applied to Health, ICNAS, University of 171
Coimbra). PiB-PET images were classified as amy- 172
loid positive or negative based on a support vector 173
machines (SVM) local classifier, which uses the voxel 174
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(SUVR) and the cerebellar grey matter as reference176
region [31].177
Conversion to dementia178
At follow-up, the patients were classified as179
“non-converter” if the diagnosis persisted until last180
assessment or “converter” in the presence of a181
dementia diagnosis established according to the182
DSM-IV-TR [34] criteria, in a consensus meeting183
with the team of neurologists and neuropsychologists184
that followed the patients.185
Neuropsychological assessment186
The baseline and follow-up comprehensive neu-187
ropsychological assessment was carried out by the188
same team of trained neuropsychologists, following a189
standard protocol and comprised the following instru-190
ments and scales:191
• Mini-Mental State Examination (MMSE) [35,192
36] - the MMSE is a brief screening instrument193
to assess global cognitive performance. The Por-194
tuguese version was applied, and normative data195
was >27 for more than 11 years of education and196
>22 for 11 or less years of education [36].197
• Battery of Lisbon for the Assessment of198
Dementia (BLAD) [37, 38] - the BLAD is a199
comprehensive neuropsychological battery that200
includes some tests from the Wechsler Memory201
Scale [39] and has been validated for the Por-202
tuguese population. This battery includes tests203
for the following cognitive domains: attention204
(Cancellation Task); verbal initiative (Seman-205
tic Fluency), motor and graphomotor initiatives;206
verbal comprehension (a modified version of207
the Token Test); verbal and non-verbal rea-208
soning (Interpretation of Proverbs and the209
Raven’s Coloured Progressive Matrices – Ab210
series); orientation (Personal, Spatial, and Tem-211
poral Orientation); visuo-constructional abilities212
(Cube Copy); planning and visuospatial/praxis213
abilities (Clock Draw); calculation (Basic Writ-214
ten Calculation); immediate memory (Digit215
Span Forward); visual memory (Visual Repro-216
duction Test); working memory (Digit Span217
Backward); learning and verbal memory (Ver-218
bal Paired-Associate Learning, Logical Memory219
and Word Recall).220
• California Verbal Learning Test (CVLT) [40,221
41] - the CVLT measures verbal learning and222
assesses constructs such as repetition learning, 223
serial position effects, semantic organization, 224
intrusion, and proactive interference. The word 225
lists (List A and List B) are made up of 16 items 226
from 4 different categories of “shopping list” 227
items. The trial of interest (better discriminating 228
ability for different stages of cognitive decline) 229
[42] considered for the present study was the 230
total number of words from List A correctly 231
recalled on the first 5 learning trials (CVLT 5 232
Trials Total Recall). 233
• Trail Making Test (part A and part B) [43, 44] 234
- the TMT task measures sustained attention, 235
visuomotor processing speed (part A), visuospa- 236
tial working memory and cognitive flexibility 237
(part B). The part A consists of 25 circles num- 238
bered 1–25 distributed over a sheet of paper and 239
the patient should draw lines to connect the num- 240
bers in ascending order. In Part B there are 25 241
circles as well, but the circles include both num- 242
bers (1–13) and letters (A–M) and the patient has 243
to draw lines to connect them all in an ascend- 244
ing pattern with the added task of alternating 245
between the numbers and letters (i.e., 1-A-2-B- 246
3-C, etc.). 247
• Geriatric Depression Rating Scale (GDS) 248
[45–47] - the GDS is a self-report instrument 249
used specifically to identify depressive symp- 250
tomatology in the elderly. For this study, a 251
Portuguese version of a short form (15 items) 252
was applied [47]. 253
• Subjective Memory Complaints Scale (SMC) 254
[48, 49] - the SMC scale comprises 10 individ- 255
ual questions for the assessment of subjective 256
memory complaints, with total scores ranging 257
from 0 (absence of complaints) to 21 (maximal 258
complaints score). 259
• Blessed Dementia Rating Scale (BDRS) [50, 51] 260
- the BDRS is a brief behavioral scale based on 261
the interview of a close informant. This scale 262
is composed of 22 items that address daily life 263
activities, habits and changes in personality. 264
Statistical analysis 265
For baseline comparison of demographic and clin- 266
ical data between groups the Student’s t test and 267
Pearson’s χ2 test were used, for numerical and nom- 268
inal data, respectively. All tests were 2-tailed and a 269
p-value <0.05 was assumed to be statistically sig- 270
nificant. The neuropsychological assessments were 271
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norms for the Portuguese population [37, 38] and z273
scores were calculated. The comparison of neuropsy-274
chological results between the group that progressed275
to dementia during follow-up and the group that276
remained with MCI was conducted using Student’s277
t test. To explore the effect of impairment in neu-278
ropsychological tests on the time to conversion to279
dementia during follow-up, first the proportional280
hazards assumption for neuropsychological predic-281
tors was tested by adding time dependent covariates282
(interaction of predictors and a function of survival283
time) and then a Cox Proportional Hazards Regres-284
sion model was conducted. The hazard or risk of285
conversion to dementia for the neuropsychologi-286
cal tests that were significantly different between287
converter and non-converter groups was computed.288
Time to event was calculated as the interval from289
the initial baseline evaluation to the diagnosis of290
dementia. For cases that remained non-demented,291
time was censored at the date of the last clin-292
ical/neuropsychological assessment. Kaplan-Meier293
curves analyzing the incidence of dementia accord-294
ing to the z scores of the lowest and the highest295
tercile were depicted. For comparison of curves, we296
opted for the Gehan-Breslow test since one group had297
a higher risk of conversion due to the significantly298
lower cognitive performance at baseline.299
Statistical analyses were performed using IBM300
SPSS Statistics 25 for Windows (2017 SPSS Inc.,301
an IBM Company) package.302
RESULTS303
One hundred and ten patients with MCI due to304
AD were enrolled. During the follow-up period305
(2.69 ± 1.56 years for converters and 2.67 ± 1.39306
for non-converters), 63 patients (56%) progressed to
dementia and 50 (44%) did not. Demographic and 307
clinical data are reported in Table 1. The convert- 308
ers at the baseline assessment were younger than 309
the non-converters; however, for mean follow-up 310
time, education level, gender, depressive symptoma- 311
tology, cognitive complaints, and independence at 312
daily activities, no statistically significant differences 313
were found (Table 1). 314
The results of a comprehensive neuropsycholog- 315
ical assessment showed the presence of impairment 316
(z score<–1) in measures of attention and executive 317
functions (Trail Making Test A and B), orienta- 318
tion, verbal learning and episodic memory (Word 319
Recall; Logical Memory immediate recall; Logi- 320
cal Memory delayed recall; Verbal Paired-Associate 321
Learning; California Verbal Learning Test 5 Tri- 322
als Total Recall) for both groups. In a measure 323
of language comprehension (Token Test), only the 324
converters showed impairment. Moreover, convert- 325
ers scored significantly lower than non-converters 326
at measures of verbal initiative (Semantic Fluency), 327
non-verbal reasoning (Raven’s Coloured Progressive 328
Matrices), and episodic memory (Logical Memory 329
immediate recall). Noteworthy, a trend toward sta- 330
tistical significance was found for the delayed recall 331
condition of the Logical Memory test with converters 332
scoring lower than non-converters at baseline assess- 333
ment (Table 2). 334
A multivariate Cox proportional hazards regres- 335
sion model was applied to identify the independent 336
predictors associated with time to conversion. The 337
proportional hazards assumption was tested for 338
each predictor (Age: Hazard Ratio [HR] = 1.020, 339
CI: 0.990–1.052, p = 0.192; Semantic Fluency: 340
HR = 0.965, CI: 0.804–1.159, p = 0.704; Logi- 341
cal Memory (immediate recall): HR = 0.981, CI: 342
0.834–1.155, p = 0.821; Raven Coloured Progressive 343
Table 1
Baseline demographic and clinical characteristics of non-converters and converters
Non-converter Converter p
n = 49 mean (n = 24) n = 61
Age at first assessment, y, mean (SD) 70.1 (6.2) 65.4 (7.3) <0.001∗
Formal education, y, mean (SD) 10.7 (4.6) 10.2 (4.8) 0.591
Gender, female/male, n 28/22 35/27 1.000#
Follow-up time, y, mean (SD) 2.7 (1.4) 2.7 (1.6) 0.921
Time between onset of symptoms and first 2.4 (1.5) 2.2 (1.2) 0.576
neuropsychological assessment, mean (SD)
Geriatric Depression Scale, mean (SD) 5.1 (3.4) 5.8 (4.5) 0.420
Subjective Memory Complaints Scale, mean (SD) 10.3 (4.6) 10.2 (4.1) 0.959
Blessed Dementia Rating Scale, mean (SD) 3.1 (1.9) 3.4 (2.0) 0.528
Mini-Mental State Examination, mean (SD) 26.4 (2.2) 25.6 (2.4) 0.084
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Table 2
Baseline neuropsychological performances of non-converters and converters
Cognitive domain Non-converter Converter p Cohen’s d
Neuropsychological test (n = 49) (n = 61)
• attention and executive functions
Cancellation Task 0.26 (1.17) 0.04 (1.37) 0.406 0.14
Digit Span Backward 0.06 (0.90) –0.09 (1.20) 0.488 0.12
Clock Draw 0.05 (1.49) –0.37 (1.53) 0.216 0.28
Trail Making Test A –1.31 (1.70)# –1.36 (1.85)# 0.896 0.02
Trail Making Test B –1.97 (1.84)# –1.63 (1.79)# 0.413 –0.18
• initiative
Semantic Fluency –0.07 (1.33) –0.86 (1.48) 0.004∗ 0.54
Motor Initiative –0.27 (1.80) –0.70 (1.90) 0.238 0.23
Graphomotor Initiative 0.05 (0.76) –0.13 (1.00) 0.319 0.21
• reasoning
Raven Coloured Progressive Matrices 0.05 (1.06) –0.60 (1.43) 0.009∗ 0.48
Interpretation of Proverbs 0.73 (1.23) 0.34 (1.82) 0.211 0.21
• orientation
Personal, Spatial and Temporal Orientation –2.32 (2.45)# –2.23 (2.35)# 0.846 –0.04
• calculation
Basic Written Calculation –0.47 (1.00) –0.59 (1.17) 0.582 0.08
• visuo-constructional abilities
Cube Copy 1.54 (1.95) 1.33 (2.37) 0.656 0.11
• language
Token Test –0.59 (1.11) –1.17 (1.83)# 0.113 0.36
• memory and learning
Visual Reproduction 1.45 (1.30) 0.58 (0.99) 0.150 0.77
Digit Span Forward 0.55 (1.30) 0.42 (1.34) 0.622 0.08
Word Recall –1.25 (1.44)# –1.77 (1.57)# 0.093 0.35
Logical Memory (immediate recall) –1.17 (1.13)# –1.92 (1.53)# 0.005∗ 0.53
Logical Memory (delayed recall) –1.99 (1.40)# –2.64 (0.93)# 0.056 0.53
Forgetting Index (1) –1.23 (2.38)# –1.79 (2.78)# 0.266 0.26
Verbal Paired-Associate Learning –1.18 (1.20)# –1.58 (1.54)# 0.139 0.25
CVLT 5 Trials Total Recall –3.14 (1.36)# –3.69 (0.95)# 0.077 0.42
Means of z scores calculated according to the equation [z = (x–mean)/SD]; Group comparisons were performed with independent samples
Student’s t test. ∗Statistically significant p < 0.05. #Presence of impairment (z score<–1). (1)Forgetting Index = [(LM delayed recall –LM
immediate)/LM immediate)]*100. CVLT, California Verbal Learning Test.
Matrices: HR = 1.217, CI: 1.005–1.475, p = 0.045).344
Only the clinical and neuropsychological measures345
that differentiate the groups were included as predic-346
tors. In the first model, only the clinical predictor347
(age) by the method enter was included. Age at348
baseline was not associated with time to event (con-349
version to dementia). Neuropsychological predictors350
were subsequently subjected to multivariate Cox pro-351
portional hazards regression analysis (Table 3). The352
Semantic Fluency was added to the model and was353
a significant predictor (HR = 0.762, CI: 0.634–0.916,354
p = 0.004), whereas the Logical Memory (immedi-355
ate recall) in the presence of Semantic Fluency did356
not reach significance as predictor (HR = 0.852, CI:357
0.704–1.031, p = 0.099) (Table 3). However, the Log-358
ical Memory (immediate recall) was a significant359
predictor if entered first in the model (data not shown360
in Table 3; HR = 0.797, CI: 0.663–0.957, p = 0.015).361
When the Raven Coloured Progressive Matrices was362
added to the model, the other predictors lost their363
significance (Semantic Fluency: HR = 0.835, CI: 364
0.691–1.009, p = 0.062; Logical Memory (immedi- 365
ate recall): HR = 0.898, CI: 0.738–1.092, p = 0.281). 366
In the final model, only the Raven Coloured Pro- 367
gressive Matrices, a test of non-verbal reasoning, 368
remained significant as a predictor of time to con- 369
version to dementia (HR = 0.712, CI: 0.566–0.894, 370
p = 0.004). A decrease of one unit (z score) in Raven 371
Coloured Progressive Matrices was associated with 372
a 29% increase in the risk of conversion to dementia 373
(Table 3). 374
For the Kaplan-Meier curves, the comparison 375
was between the highest and the lowest terciles 376
of the Raven Coloured Progressive Matrices scores 377
to assess the differences in time to conversion to 378
dementia. Because at baseline both groups showed 379
normative results, the presentation of Kaplan-Meier 380
curves comprised the lowest and the highest ter- 381
ciles, instead of impaired and unimpaired z scores, 382
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Table 3
Multivariate Cox proportional-hazard regression models for predictors of conversion to dementia
Predictors (n = 110; event/conversion to dementia = 61; censured = 49) HR 95%CI p
Multivariate analysis
Model 1 – demographic variable (enter method)
Age (mean, y) 0.984 0.950–1.019 0.376
Model 2 – cognitive predictors (enter method)
Semantic Fluency (mean, z score) 0.762 0.634–0.916 0.004∗
Model 3 – cognitive predictors (enter method)
Semantic Fluency (mean, z score) 0.804 0.664–0.974 0.026∗
Logical Memory (immediate recall) (mean, z score) 0.852 0.704–1.031 0.099
Model 4 – cognitive predictors (enter method)
Semantic Fluency (mean, z score) 0.835 0.691–1.009 0.062
Logical Memory (immediate recall) (mean, z score) 0.898 0.738–1.092 0.281
Raven’s Coloured Progressive Matrices (mean, z score) 0.712 0.566–0.894 0.004∗
CI, Confidence Interval; HR, Hazard Ratio; ∗Statistically significant (p < 0.05).
According to the Kaplan-Meier curves, for z scores384
in the lowest tercile (z score range: –2.88 to –0.96)385
after 3 years of follow-up approximately 50% of386
patients had converted to dementia, whereas for the387
highest tercile (z score range: 0.59 to 1.82) the conver-388
sion of approximately 50% of patients occurred later,389
after 4 years of follow-up. Accordingly, a significant390
difference between Kaplan-Meier curves was found391
(χ2(1) = 6.131; p = 0.013).392
DISCUSSION393
Patients with MCI due to AD that converted to394
dementia during the follow-up period were more395
impaired at the baseline in neuropsychological tests396
assessing verbal fluency, non-verbal reasoning, and397
episodic memory, as compared to non-converters. An398
interesting result is that only non-verbal reasoning,399
assessed through Raven Coloured Progressive Matri-400
ces, remained significant as a predictor of time to401
conversion to dementia in a multivariate model.402
Several studies have previously evidenced the403
predictive value of neuropsychological measures404
to assess time to conversion to dementia in MCI405
patients with unknown biomarker status [22, 52–54].406
Noteworthy, some studies highlighted that not only407
episodic memory performance but also other cogni-408
tive areas, namely executive functions and language409
tests, are associated with a higher likelihood of pro-410
gression from MCI to dementia during follow-up [14,411
21, 55–57]. Thus, it would be plausible to expect a412
similar contribution of neuropsychological testing for413
patients with MCI due to AD.414
According to our results, cognitive areas associated415
with reasoning and fluid intelligence, that reveal lit-416
tle decline until more advanced phases of AD, as can417
be seen in the normative results of our MCI patients,418
can contribute significantly to predict time to con- 419
version. As previously mentioned, only non-verbal 420
reasoning, assessed through Raven Coloured Pro- 421
gressive Matrices, remained significant as a predictor 422
of time to conversion to dementia in a multivari- 423
ate model. For each standard deviation reduction in 424
the z score of Raven Coloured Progressive Matrices 425
score the risk of conversion to dementia increased 426
approximately 30%. This test is a measure of fluid 427
intelligence that demands several abilities as visual- 428
perceptual, process integration, logical reasoning, 429
and cognitive flexibility [58]. The contribution of the 430
Raven Coloured Progressive Matrices to predict time 431
to conversion to dementia has been, to the best of our 432
knowledge, largely neglected in the literature. Fluid 433
intelligence has been addressed as a proxy of cogni- 434
tive reserve [59]. In AD patients, a higher cognitive 435
reserve was associated with slower clinical progres- 436
sion in predementia stages, but after the onset of 437
dementia it appears to have the opposite effect and 438
accelerate the cognitive decline [60]. Interestingly, 439
in a different cohort study from the same memory 440
clinic in Lisbon, in amnestic MCI patients without 441
amyloid status information, an association of perfor- 442
mance in Raven Coloured Progressive Matrices with 443
long-term (10 years) diagnostic stability was also 444
found [61]. Likewise, a large community-based study 445
with non-demented subjects, the Framingham cohort 446
prospective study, showed that a test of abstract rea- 447
soning was a strong predictor of long-term (22 years) 448
conversion to dementia [62]. In the present study, the 449
Raven Coloured Progressive Matrices test was found 450
to be the stronger predictor of conversion to dementia 451
at a shorter (3 years) term in patients with MCI due 452
to AD. 453
As foreseeable, most of the MCI due to AD patients 454













8 D. Silva et al. / Neuropsychological Prognosis in MCI Due to AD
Fig. 2. Kaplan-Meier analysis of the incidence of dementia among patients in the lowest and in the highest tercile of the z scores.
patients that converted to dementia during follow-456
up were younger at baseline than patients that did457
not convert, with no differences being found in dura-458
tion of symptoms, presence of depressive symptoms,459
and years of formal education. This result seems to460
be in contradiction to longitudinal studies of conver-461
sion from MCI to AD that commonly report higher462
risk of conversion to dementia for the older patients463
[63, 64]. However, the influence of age in cognitive464
decline for AD patients is not straightforward and465
some studies have revealed that AD patients starting466
the symptoms earlier had a less benign course with467
higher rate of cognitive decline [65]. Notwithstanding468
the difference at baseline, age was not a significant 469
predictor of time to conversion. 470
The present study has some limitations that might 471
be addressed in future studies. Obtaining a longer 472
follow-up would be important. Replication of the 473
present findings in other studies recruiting patients 474
at a similar clinical stage would be needed. The 475
genotyping of Apolipoprotein E (APOE) 4 is not 476
recommended in a clinical context [66] and for that 477
reason was not available, and this is a limitation of the 478
present study. Patients did not undergo all neuronal 479
injury biomarkers, so it was not possible to assess 480
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dementia. Not all patients with MCI undergo the diag-482
nostic procedures with biomarkers, which are costly483
and invasive, thus the patients diagnosed with MCI484
due to AD are not representative of the AD population485
in a memory clinic.486
The major strengths of the present study are the487
sample high likelihood of having AD neurodegen-488
eration according to the diagnostic criteria and the489
minor loss to follow-up of the cohort. As future per-490
spectives, predicting conversion of MCI due to AD491
to dementia might be improved by machine learning492
techniques, namely by a feature selection ensemble493
approach to automatically choose the best neuropsy-494
chological predictors of future conversion, as was495
already done for MCI patients without amyloid status496
information [67]. Anticipating a precision medicine497
approach, it would important to refine risk models498
that can provide reliable prognostic information to499
the individual patient with MCI due to AD [68].500
It has been an extraordinary recent advance being501
able to diagnose AD at an early clinical stage. Still,502
after being diagnosed with MCI due to AD, patients503
and families need to make important life decisions504
and future planning, and expectedly wish to get a505
reliable estimation of the disease progression. To506
the best of our knowledge, the present study is507
the first to explore the differential contribution of508
routine neuropsychological tests to predict time to509
conversion to dementia among patients diagnosed510
with MCI due to AD. Neuropsychological tests,511
namely assessing verbal fluency, episodic memory,512
and particularly non-verbal reasoning assessed with513
the Raven Coloured Progressive Matrices, may con-514
tribute to predict stability or conversion to dementia515
at a clinically meaningful time window.516
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Abrunhosa A, Castelo-Branco M (2018) Can 11C-PiB-PET 716
relative delivery R1 or 11C-PiB-PET perfusion replace 18F- 717
FDG-PET in the assessment of brain neurodegeneration? J 718
Alzheimers Dis 65, 89-97. 719
[32] Janelidze S, Stomrud E, Brix B, Hansson O (2019) Towards 720
a unified protocol for handling of CSF before -amyloid 721
measurements. Alzheimers Res Ther 11, 63. 722
[33] Mattsson N, Zetterberg H, Hansson O, Andreasen N, Par- 723













D. Silva et al. / Neuropsychological Prognosis in MCI Due to AD 11
Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M,725
Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ,726
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